SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Dunn, N. R.
Right arrow Articles by Shakir, S. A. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dunn, N. R.
Right arrow Articles by Shakir, S. A. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Alzheimer's Disease
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Adverse effects associated with the use of donepezil in general practice in England

N. R. Dunn

Drug Safety Research Unit, Bursledon Hall, Southampton, UK; Department of Primary Medical Care Aldermoor Health Centre Aldermoor Close Southampton SO16 5ST UK; nick.dunn{at}soton.ac.uk

G. L. Pearce

S. A. W. Shakir

Drug Safety Research Unit, Bursledon Hall, Southampton, UK

Donepezil is an acetylcholinesterase inhibitor indicated for the symptomatic treatment of mild to moderate Alzheimer's disease. It is reported to have a relatively favourable side-effect profile. We report here on a pharmacovigilance study carried out post-marketing in England. An observational cohort study using the technique of Prescription-Event Monitoring was carried out. Some 1762 patients (mean age 72.9 years; 42% male) were followed up for 6 months minimum. The commonest adverse events were nausea, diarrhoea, malaise, dizziness and insomnia. Aggression, agitation and abnormal dreams were uncommonly associated with the drug. There were no cardiac rhythm disturbances or liver disorders causally associated. The commonest adverse drug reactions are already reported in the product information. Given the relatively small size of this cohort, the signals of abnormal dreams and psychiatric disturbance as possible adverse drug reactions need further investigation in carefully planned studies.

Key Words: abnormal dreams • aggression • donepezil • pharmacovigilance • prescription-monitoring

Journal of Psychopharmacology, Vol. 14, No. 4, 406-408 (2000)
DOI: 10.1177/026988110001400410


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
ChestHome page
W. Moraes, D. Poyares, L. Sukys-Claudino, C. Guilleminault, and S. Tufik
Donepezil Improves Obstructive Sleep Apnea in Alzheimer Disease: A Double-Blind, Placebo-Controlled Study
Chest, March 1, 2008; 133(3): 677 - 683.
[Abstract] [Full Text] [PDF]


Home page
Emerg. Med. J.Home page
T Suleyman, P Tevfik, G Abdulkadir, and S Ozlem
Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil.
Emerg. Med. J., August 1, 2006; 23(8): 641 - 642.
[Abstract] [Full Text] [PDF]



Advertisement